NCT00123630View on ClinicalTrials.gov

A Pilot Study of the Treatment of Eosinophilic Esophagitis With Omalizumab

PHASE2CompletedINTERVENTIONAL

Enrollment

30

Participants

Timeline

Start Date

November 30, 2005

Primary Completion Date

January 31, 2010

Study Completion Date

January 31, 2010

Conditions

Esophagitis

Interventions

DRUG

omalizumab

omalizumab dosed IV based on IgE level and weight every 2 - 4 weeks

DRUG

Placebo

Placebo given IV once every 2-4 weeks based on weight

Trial Locations (1)

84132

University of Utah HSC, Salt Lake City

Sponsors

Collaborators (1)

Novartis Pharmaceuticals

All Listed Sponsors

collaborator

Novartis Pharmaceuticals

INDUSTRY

lead

University of Utah

OTHER